ASH Annual Meeting and Exposition

ASH Annual Meeting and Exposition

December 12, 2019
1 min read

Doptelet cost-effective, avoids transfusions for CLD-related thrombocytopenia

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Treatment with Doptelet was cost-effective for the treatment of thrombocytopenia in patients with chronic liver diseases compared with other treatment options, according to data presented at the American Society of Hematology meeting.

The study compared Doptelet (avatrombopag, Dova Pharmaceuticals), an oral thrombopoietin receptor agonist approved by both the FDA and the European Medicines Agency (EMA) for treatment of thrombocytopenia in adults with CLD who are scheduled to undergo a procedure, with platelet transfusion and Mulpleta (lusutrombopag, Shinogi).

“The results showed that the use of avatrombopag is a practical strategy compared with the cost of both platelet transfusion and lusutrombopag, as it saves costs and reduces the need for prophylactic platelet transfusions and is as such a cost-effective treatment for thrombocytopenia in patients with CLD,” Kavita Aggarwal, vice president of medical affairs at Dova Pharmaceuticals, said in a press release.

Lee F. Allen, MD, PhD, from Dova Pharmaceuticals, and colleagues developed a decision-tree model from a U.S. payer perspective with data on clinical events from registration trails and potential long-term complications in scenario analyses.

Results showed that avatrombopag reduced the need for platelet transfusions and produced cost-savings per person compared with “intended platelet transfusion” (80% fewer prophylactic platelet transfusions) for a relative cost savings of $4,250. The cost for lusutrombopag was $5,819 higher than avatrombopag due to a need for 15% more platelet transfusions.

The investigators observed similar results in both higher and lower platelet count subgroups and that use of avatrombopag remained cost-saving over a wide range of variables, with incremental cost-effectiveness including decreased costs and avoiding prophylactic platelet transfusions.


Allen LF, et al. Abstract 3454. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2019; Orlando.

Disclosures: Aggarwal and Allen are employees of Dova Pharmaceuticals.